Edoxaban

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Non-valvular Atrial Fibrillation

Conditions

Non-valvular Atrial Fibrillation

Trial Timeline

Feb 26, 2021 → Nov 27, 2024

NCT ID

NCT04747496

About Edoxaban

Edoxaban is a pre-clinical stage product being developed by Daiichi Sankyo for Non-valvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT04747496. Target conditions include Non-valvular Atrial Fibrillation.

What happened to similar drugs?

2 of 3 similar drugs in Non-valvular Atrial Fibrillation were approved

Approved (2) Terminated (0) Active (1)

✅Edoxaban + Aspirin and Clopidogrel + Aspirin and WarfarinDaiichi SankyoApproved

✅ApixabanBristol Myers SquibbApproved

🔄DU-176b 15mg + DU-176b 30mg + DU-176b 60mgDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05804747	Pre-clinical	Completed	Feb 16, 2023	Jul 28, 2025	Atrial Fibrillation
NCT04747496	Pre-clinical	Completed	Feb 26, 2021	Nov 27, 2024	Non-valvular Atrial Fibrillation
NCT04594915	Pre-clinical	Completed	Aug 14, 2020	Jun 21, 2023	Atrial Fibrillation
NCT04519944	Pre-clinical	Completed	Jun 30, 2020	Jul 6, 2023	Non-valvular Atrial Fibrillation
NCT04171726	Phase 3	UNKNOWN	Aug 1, 2019	Sep 1, 2023	Aortic Valve Stenosis
NCT03840291	Approved	Completed	May 19, 2019	Aug 1, 2024	Atrial Fibrillation
NCT03247569	Pre-clinical	Completed	Oct 18, 2017	Feb 28, 2022	Atrial Fibrillation
NCT03247582	Pre-clinical	Completed	Aug 2, 2017	May 3, 2022	Atrial Fibrillation
NCT02952599	Pre-clinical	Completed	Mar 27, 2017	Oct 29, 2019	Venous Thromboembolism
NCT02951039	Pre-clinical	Completed	Feb 21, 2017	Oct 15, 2020	Atrial Fibrillation
NCT02964949	Pre-clinical	Completed	Jan 24, 2017	Oct 9, 2018	Atrial Fibrillation
NCT02943993	Pre-clinical	Completed	Apr 6, 2016	Dec 1, 2020	Venous Thromboembolism
NCT02944019	Pre-clinical	Completed	Aug 1, 2015	Apr 13, 2022	Atrial Fibrillation
NCT02448901	Pre-clinical	UNKNOWN	Apr 1, 2015	Mar 1, 2016	Heart Failure

Competing Products

17 competing products in Non-valvular Atrial Fibrillation

See all competitors

Product	Company	Stage	Hype Score
DU-176b 15mg + DU-176b 30mg + DU-176b 60mg	Daiichi Sankyo	Phase 3	40
Edoxaban + Aspirin and Clopidogrel + Aspirin and Warfarin	Daiichi Sankyo	Approved	39
Edoxaban	Daiichi Sankyo	Pre-clinical	26
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Apixaban + Warfarin	Pfizer	Pre-clinical	26
Warfarin + Apixaban	Pfizer	Pre-clinical	26
Apixaban	Bristol Myers Squibb	Approved	43
Apixaban	Bristol Myers Squibb	Pre-clinical	18
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban(Xarelto,BAY 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto,Bay 59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Warfarin	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY-597939) + VKAs	Bayer	Pre-clinical	23
Non-VKA Oral Anticoagulants (NOAC)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto_ BAY59-7939)	Bayer	Pre-clinical	23
Rivaroxaban (Xarelto, BAY59-7939) + Apixaban (Eliquis) + Dabigatran etexilate (Pradaxa) + Warfarin (Marevan)	Bayer	Pre-clinical	15